drugset / Trial / NCT01323205

Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia

NCT01323205

Phase 2 Completed 100 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to explore the safety, tolerability, and potential clinical efficacy of JNJ 40411813 in schizophrenic patients.

Timeline

Start
2011-05
Primary completion
2012-11
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-40411813 Small molecule 150 mg Oral
Background Amisulpride Small molecule
Background Aripiprazole Other / unclassified
Background Benperidol Small molecule
Background CLOTHIAPINE Small molecule
Background Chlorpromazine Small molecule
Background Clozapine Other / unclassified
Background Flupentixol Unknown
Background Fluphenazine Decanoate Small molecule
Background Haloperidol Other / unclassified
Background Levomepromazine Small molecule
Background Melperone Small molecule
Background Olanzapine Small molecule
Background Paliperidone Unknown
Background Pipamperone Small molecule
Background Quetiapine Small molecule
Background Risperidone Other / unclassified
Background Zuclopenthixol Unknown

Indications